SCHEMBL3520561

SCHEMBL3520561

CC(C)CN(Cc1ccc2c(c1)OCO2)C(=O)C1CN(Cc2ccccc2)CCO1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 2/20 0.56
LMNA P02545 4/20 0.47
KDM4E B2RXH2 2/20 0.47
OPRD1 P41143 1/20 0.46
SIGMAR1 Q99720 2/20 0.46
THRB P10828 1/20 0.45
KMT2A Q03164 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 2/20 0.43
GRN P28799 1/20 0.43
SORT1 Q99523 1/20 0.43
TSHR P16473 1/20 0.43
UBE2M P61081 1/20 0.42
DCUN1D1 Q96GG9 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520200 0.96 PROKR2 (0.59) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3518041 0.96 PROKR2 (0.59) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3518033 0.96 PROKR2 (0.59) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3518564 0.94 PROKR2 (0.61) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3517508 0.94 PROKR2 (0.63) PROKR2LMNAKDM4EKMT2ACYP2D6
SCHEMBL387975 0.94 PROKR2 (0.63) PROKR2LMNAKDM4EKMT2ACYP2D6
SCHEMBL3516623 0.94 PROKR2 (0.63) PROKR2LMNAKDM4EKMT2ACYP2D6
SCHEMBL3516520 0.94 PROKR2 (0.60) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3517887 0.93 PROKR2 (0.60) PROKR2LMNAKDM4EOPRD1KMT2A
SCHEMBL3518557 0.93 PROKR2 (0.55) PROKR2LMNAKDM4EOPRD1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885LMNA 571/4885KDM4E 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.